zoledronic acid has been researched along with Disease Models, Animal in 200 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.00) | 18.2507 |
| 2000's | 36 (18.00) | 29.6817 |
| 2010's | 146 (73.00) | 24.3611 |
| 2020's | 16 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Biguetti, CC; Custódio, IC; Duarte, MAH; Ervolino, E; Fakhouri, WD; Faverani, LP; Mahmoud, RH; Matsumoto, MA; Silva, RBP; Simionato, GB | 1 |
| Aung, KT; Dang, AT; Hara, ES; Ishibashi, K; Kuboki, T; Mikai, A; Nawachi, K; Ono, M; Ono-Kimura, A; Oohashi, T; Tanaka, Y; Tosa, I | 1 |
| Biggin, A; Cheng, TL; Holman, AE; Lee, LR; Li, X; Little, DG; Munns, CF; O'Donohue, AK; Schindeler, A; Vasiljevski, ER | 1 |
| Dong, R; Sun, L; Zhang, S; Zhang, W | 1 |
| Otto, S; Poxleitner, P; Schmelzeisen, R; Seibert, LM; Steybe, D; Stoddart, MJ; Voss, PJ; Zeiter, S | 1 |
| Ding, D; Feng, G; Jin, Q; Ma, L; Pei, X; Wang, L; Yan, J; Yang, Y; Zhou, Y | 1 |
| Guo, XE; Hu, YJ; Lu, WW; Peng, Y; Tang, B; Wang, J; Wang, Z; Xu, L | 1 |
| Gu, J; Pan, W; Wang, J; Wang, S; Xu, J; Xu, S; Zhang, C | 1 |
| Helm, A; Rao, NJ; Wang, JY; Yu, RQ; Zheng, LW | 1 |
| Cohen, G; Cohen, T; Doppelt, O; Elimelech, R; Eskander-Hashoul, L; Tamari, T; Zigdon-Giladi, H | 1 |
| Hibi, H; Nakamichi, E; Sakai, K; Toyama, N; Urata, Y; Watanabe, J | 1 |
| Adachi, N; Atsuta, I; Ayukawa, Y; Furuhashi, A; Imai, M; Koyano, K; Sanda, K; Yasunami, N | 1 |
| Cabral, WA; Collins, FS; Cubria, MB; DuBose, A; Erdos, MR; Kamalapathy, P; Karim, L; Masoudi, A; Nazarian, A; Oftadeh, R; Snyder, BD; Suarez, S | 1 |
| Bobyn, JD; Deo, N; Little, DG; Schindeler, A | 1 |
| Du, Y; Kong, F; Li, J; She, P; Yao, C; Zhang, F; Zhang, Q | 1 |
| Asoda, S; Ito, E; Iwasaki, R; Kaneko, Y; Kawana, H; Kobayashi, T; Matsumoto, M; Miyamoto, K; Miyamoto, T; Nakagawa, T; Nakamura, M; Nakamura, S; Okada, H; Sato, Y; Soma, T; Watanabe, H | 1 |
| Fujita, R; Hamano, H; Hiratsuka, S; Iwasaki, N; Kobayashi, H; Sato, D; Shimizu, T; Takahata, M | 1 |
| Blue, ME; Boskey, AL; Doty, SB; Lukashova, L; Shapiro, JR | 1 |
| Amizuka, N; Cui, P; Li, M; Liu, H; Sun, J; Sun, Q | 1 |
| Cheng, TL; Kneissel, M; Kramer, I; Little, DG; Mikulec, K; Munns, C; Peacock, L; Schindeler, A | 1 |
| Acevedo, AC; Chaves, SB; de Souza, MP; Ferrare, N; Figueiredo, PT; Guimarães, ATB; Leite, AF; Macedo, SB; Melo, NS; Moreira, AMR; Moura, HF; Vilarinho, JLP | 1 |
| Allen, MR; Alvarez, MB; Bidwell, JP; Burr, DB; Childress, P; Condon, KW; Davis, H; He, Y; Hernandez-Buquer, S; Plotkin, LI; Robling, AG; Shao, Y; Stayrook, KR; Warden, SJ; Wek, RC; Yang, FC | 1 |
| Cheng, TL; Deo, N; Little, DG; Mikulec, K; Peacock, L; Schindeler, A | 1 |
| Ehrenfeld, M; Martin Jurado, O; Nehrbass, D; Otto, S; Pautke, C; Stoddart, MJ; Zeiter, S | 1 |
| Borges, LCFS; Chaud, MV; de Almeida, AD; Grotto, D; Hataka, A; Leite, FG; Rebelo, MA; Viroel, FJM | 1 |
| Farei-Campagna, J; Jentzsch, T; von Rechenberg, B; Werner, CM; Zwolak, P | 1 |
| Amini, P; Dehghan, A; Doulati, S; Rezaeian, L; Zandi, M | 1 |
| Cho, SH; Kang, SH; Kim, H; Kim, I; Lee, W; Park, JB | 1 |
| Leung, YY; Rao, NJ; Wang, JY; Yu, RQ; Zheng, LW | 1 |
| Liu, X; Lu, E; Mao, C; Qin, A; Xu, X; Zhang, X | 1 |
| Buehlmann, D; Grandjean, J; Rudin, M; Xandry, J | 1 |
| Bech, M; Guizar-Sicairos, M; Isaksson, H; Mathavan, N; Schaff, F; Tägil, M; Turunen, MJ | 1 |
| Cheng, J; Jia, X; Liu, G; Shao, Z; Shen, Z | 1 |
| Bereket, C; Cakir-Özkan, N; Önger, ME; Polat, AV; Sener, I | 1 |
| Dimmen, S; Hjorthaug, GA; Madsen, JE; Niratisairak, S; Nordsletten, L; Reinholt, FP; Søreide, E | 1 |
| Agrogiannis, G; Anagnostopoulos, C; Anousakis-Vlachochristou, N; Benetos, G; Cokkinos, D; Drakopoulou, M; Georgakopoulos, A; Karanasos, A; Kotronias, R; Koutagiar, I; Latsios, G; Metaxas, M; Papalois, A; Papanikolaou, A; Patsouris, E; Pianou, N; Stathogiannis, K; Synetos, A; Tousoulis, D; Toutouzas, K; Tsiamis, E | 1 |
| Chatani, M; Funatsu, T; Isawa, M; Karakawa, A; Kuritani, M; Negishi-Koga, T; Sakai, N; Takami, M | 1 |
| Du, Y; Jin, Z; Li, Y; Sun, T; Tian, J; Xue, H | 1 |
| Allen, MR; Aref, MW; Byiringiro, I; Chen, N; Dunn, KW; Hammond, MA; Kamocka, MM; McCarthy, BP; Moe, SM; Swallow, EA; Territo, PR; Winfree, S | 1 |
| Mohammad Gholi Mezerji, N; Mousavi, M; Rajaei, S; Shokri, A; Zandi, M | 1 |
| Charlesworth, G; Daroszewska, A; Prior, A; Ralston, SH; Rose, K; Rose, L; Sarsam, N; van 't Hof, RJ | 1 |
| Ikeda, S; Kataoka, M; Tsubouchi, Y; Tsumura, H | 1 |
| Benfica, JRD; Etges, A; Langie, R; Munaretto, JC; Pacheco, VN; Ponzoni, D; Puricelli, E | 1 |
| Jin, L; Shuai, Y; Tao, Y; Wang, C; Yang, R | 1 |
| Arcos, D; Casarrubios, L; de Pablo, D; Díaz-Güemes, I; Enciso, S; Fernández-Tomé, B; Gómez-Cerezo, N; Ortega, L; Portolés, MT; Saiz-Pardo, M; Sánchez-Margallo, FM; Vallet-Regí, M | 1 |
| Bürki, A; Eckelt, U; Ferguson, SJ; Kautz, A; Kneissel, M; Korn, P; Kramer, I; Range, U; Schlottig, F; Schnabelrauch, M; Stadlinger, B; Tödtman, N | 1 |
| He, L; He, Y; Xiao, E; Zang, X; Zhang, Y; Zhao, L | 1 |
| Biguetti, CC; Constantino, DH; Custódio, IDC; De Oliva, AH; Duarte, MAH; Ervolino, E; Fakhouri, WD; Healy, K; Mahmoud, RH; Matsumoto, MA | 1 |
| Asahara, T; Asahina, I; I, T; Kuroshima, S; Nakajima, K; Sasaki, M; Sawase, T; Sumita, Y | 1 |
| Aghaloo, TL; Atti, E; Bezouglaia, O; Chaichanasakul, T; Cheong, S; Dry, SM; Kang, B; Pirih, FQ; Tetradis, S | 1 |
| Arita, K; Hashimoto, M; Hotokezaka, H; Nakano, T; Sirisoontorn, I; Tanaka, M; Yoshida, N | 1 |
| Chen, W; Gao, R; Le, A; Li, Y; Liu, Y; Mao, L; Shi, S; Wang, S; Xu, J; Zheng, Z | 1 |
| Bocca, P; Cilli, M; Cipollone, G; Di Carlo, E; Emionite, L; Morandi, F; Pistoia, V; Prigione, I; Raffaghello, L | 1 |
| Camacho-Alonso, F; López-Jornet, P; Vicente-Hernández, A | 1 |
| Atsuta, I; Chen, C; Le, AD; Liu, S; Shi, S; Zhang, Q | 1 |
| Carlton, MM; Dirksen, WP; Hildreth, BE; Lanigan, LG; London, CA; Martin, CK; Pillai, SP; Rosol, TJ; Simmons, JK; Toribio, RE; Werbeck, JL | 1 |
| Alhoniemi, E; Fagerlund, KM; Halleen, JM; Käkönen, R; Käkönen, SM; Mumberg, D; Rissanen, JP; Scholz, A; Suominen, MI; Ziegelbauer, K | 1 |
| Ashraf, S; Bennett, AJ; Burston, JJ; Chapman, V; Menhinick, MR; Poulter, CL; Sagar, DR; Walsh, DA; Xu, L | 1 |
| Çankaya, M; Dayisoylu, EH; Ersöz, S; Şenel, FÇ; Taskesen, F; Tosun, E; Üngör, C | 1 |
| Bürki, A; Eckelt, U; Ferguson, SJ; Kautz, A; Kneissel, M; Korn, P; Kramer, I; Range, U; Schlottig, F; Schnabelrauch, M; Stadlinger, B; Tödtmann, N | 1 |
| Bereket, C; Kaplan, S; Kosker, H; Sener, I; Tek, M; Turer, A | 1 |
| Dudek, AZ; Zwolak, P | 1 |
| Kokuryo, S; Sakaguchi, O; Tanaka, J; Tominaga, K; Tsurushima, H | 1 |
| Allen, MR; Chen, NX; Chen, X; Gattone, VH; Moe, SM; Newman, CL; Organ, JM | 1 |
| Kaku, N; Kawano, M; Kodera, R; Miyazaki, M; Tsumura, H; Yoshiiwa, T | 1 |
| Bronckers, AL; Ersan, N; Everts, V; Ilgüy, D; Olgaç, V; van Ruijven, LJ | 1 |
| Brance, ML; Brun, LR; Di Loreto, VE; Lupo, M; Rigalli, A | 1 |
| Chang, WC; Chen, JW; Huang, PH; Leu, HB; Lin, SJ; Peng, YJ; Tsai, HY; Tsai, SH | 1 |
| Allen, MR; Chen, NX; Gattone, VH; Moe, SM | 1 |
| Barba-Recreo, P; Burgueño, M; Del Castillo Pardo de Vera, JL; García-Arranz, M; Yébenes, L | 1 |
| Acar, N; Aslan, T; Ozbey, O; Ozenci, AM; Sahin, Z; Ustünel, I | 1 |
| Amiaud, J; Battaglia, S; Charrier, C; Gouin, F; Heymann, D; Kim, PP; Lamoureux, F; Odri, G; Redini, F | 1 |
| Bolat, F; Cınar, BM; Karaeminogullari, O; Ozkoc, G; Sezgin, N; Tandogan, RN | 1 |
| Khajuria, DK; Mahapatra, DR; Razdan, R | 1 |
| Brown, HK; Croucher, PI; Eaton, CL; Fowles, CA; Holen, I; Ottewell, PD; Reeves, KJ; Wang, N | 1 |
| Aydogan, A; Kocer, G; Kocer, M; Koskan, O; Onal, L; Ozmen, O | 1 |
| Brown, HK; Dear, TN; Haider, MT; Holen, I; Hunter, K | 1 |
| Bouvet, M; Hayashi, K; Hiroshima, Y; Hoffman, RM; Kimura, H; Matsumoto, Y; Miwa, S; Sugimoto, N; Tsuchiya, H; Uehara, F; Yamamoto, M; Yamamoto, N; Yano, S; Zhang, Y | 1 |
| Bäuerle, T; Bendl, R; Bretschi, M; Fränzle, A; Hillengass, J; Merz, M; Semmler, W | 1 |
| Aghaloo, TL; Bezouglaia, O; Cheong, S; Cirelli, JA; de Molon, RS; Dry, SM; Pirih, F; Tetradis, S | 1 |
| Bouvet, M; Chishima, T; Endo, I; Hassanein, MK; Hiroshima, Y; Hoffman, RM; Ichikawa, Y; Maawy, A; Matsuyama, R; Menen, R; Miwa, S; Momiyama, M; Mori, R; Murakami, T; Tanaka, K; Uehara, F; Yamamoto, M; Yano, S | 1 |
| Dontas, I; Khaldi, L; Lampropoulou-Adamidou, K; Lelovas, P; Papaioannou, NA; Stathopoulos, IP; Triantafillopoulos, IK; Vlamis, J | 1 |
| Kang, MK; Kim, RH; Kim, T; Lee, C; Liu, H; Park, NH; Park, S; Shi, S; Shin, KH; Williams, DW; Wu, H; Yagita, H; Yang, P | 1 |
| Balázs, P; Beretka, N; Bernhardt, R; Boros, M; Garab, D; Janovszky, Á; Mester, C; Ocsovszki, I; Piffkó, J; Szabó, A; Varga, R; Wiesmann, HP; Zombori, T | 1 |
| Feng, M; Han, W; Su, J; Zhao, H | 1 |
| Leung, WK; Li, CL; Lu, WW; Seneviratne, CJ; Zheng, LW; Zwahlen, RA | 1 |
| Hibi, H; Katagiri, W; Kawai, T; Nakamura, S; Ogata, K; Osugi, M; Sugimura, Y; Ueda, M | 1 |
| Aghaloo, TL; Bezouglaia, O; Boyce, RW; de Molon, RS; Dry, SM; Dwyer, D; Kostenuik, P; Pirih, FQ; Shimamoto, H; Tetradis, S | 1 |
| Chantry, AD; Evans, HR; Harris, W; Lawson, MA; Paton-Hough, JM; Ratnabalan, D; Snowden, JA; Walker, RE | 1 |
| Bernstein, A; Nelson, K; Poxleitner, PJ; Schmelzeisen, R; Stadelmann, V; Stoddart, MJ; Voss, PJ; Ziebart, T | 1 |
| Che, W; Dong, J; Jiang, L; Li, X; Yasen, M; Yuan, W | 1 |
| Banankhah, S; Jewett, A; Kanayama, K; Kaur, K; Nishimura, I; Park, S; Quje, DT; Sayre, JW; Tseng, HC | 1 |
| Abarrategi, A; Barba-Recreo, P; Burgueño, M; Del Castillo Pardo de Vera, JL; García-Arranz, M; Georgiev-Hristov, T; Ruiz Bravo-Burguillos, E | 1 |
| Alves, AP; Barbosa, MC; Ferreira Junior, AE; Lima Júnior, RC; Mota, MR; Ribeiro, Rde A; Silva, PG; Sousa, FB; Teófilo, CR | 1 |
| Baek, HR; Jin, YZ; Lee, JH; Lee, KM; Shin, SJ; Zheng, GB | 1 |
| Etges, A; Langie, R; Pacheco, VN; Ponzoni, D; Puricelli, E | 1 |
| Ma, C; Shen, L; Shuai, B; Xu, X; Yang, Y; Zhu, R | 1 |
| Bittermann, G; Nelson, K; Poxleitner, P; Schmelzeisen, R; Stoddart, M; Voss, PJ; Zeiter, S; Ziebart, T | 1 |
| Borke, JL; Brown, TL; Cray, J; Daoudi, A; Elsalanty, ME; Howie, RN; Kurago, Z; Medani, F; Messer, R; Raley, JN; Tran, LT; Zakhary, IE | 1 |
| Chen, K; Pan, H; Shang, G; Xu, Y; Yang, H; Yu, F | 1 |
| Aras, MH; Bozdag, Z; Cetiner, S; Demir, T; Keskinruzgar, A; Yolcu, U | 1 |
| Dong, W; Liu, J; Qi, M; Song, Z; Sun, H; Yin, L | 1 |
| Huo, L; Li, CL; Lu, WW; Seneviratne, CJ; Zheng, LW | 1 |
| Kim, JW; Kim, MR; Kim, SJ; Landayan, MEA; Tatad, JCI | 1 |
| Dalle Carbonare, L; De Franceschi, L; Matte', A; Mori, A; Perbellini, L; Schweiger, V; Siciliano, A; Valenti, MT; Zampieri, G | 1 |
| Akbarzadeh, M; Dehghan, A; Ghadermazi, K; Malekzadeh, H; Zandi, M | 1 |
| Futamura, M; Gaowa, S; Kanematsu, M; Kato, J; Matsuhashi, N; Mori, R; Tanahashi, T; Yoshida, K | 1 |
| Hasei, T; Katsumi, H; Mozume, T; Sakane, T; Watanabe, T; Yamamoto, A; Yanagi, S | 1 |
| Andresen, CJ; Bagi, CM; Berryman, E; Wilkie, D; Zakur, DE | 1 |
| Kettenberger, U; Luginbuehl, V; Pioletti, DP; Procter, P | 1 |
| Clézardin, P; Gineyts, E; Melodelima, D; Ngo, J; Roux, JP; Tardoski, S | 1 |
| Abe, T; Kishimoto, H; Nishioka, T; Segawa, E; Shinohara, M; Takaoka, K; Tamaoka, J; Ueda, H; Urade, M; Yamamura, M | 1 |
| Cha, IH; Kim, JW; Kim, MR; Kim, SJ; Landayan, ME; Lee, JY; Tatad, JC | 1 |
| Bergmaier, V; El-Shafi, N; Flügge, T; Hövener, JB; Ludwig, U; Poxleitner, P; Stadelmann, V; von Elverfeldt, D; Voss, P | 1 |
| Aras, MH; Bozdağ, Z; Çetiner, S; Demir, T; Erkılıç, S; Yanık, S | 1 |
| Fan, QM; Han, XG; Liu, XQ; Qiao, H; Qin, A; Tang, TT; Wang, TY; Wang, YG; Yu, ZF | 1 |
| Busetti, J; de Figueiredo, JA; Donos, N; Mardas, N; Mezzomo, LA; Scarparo, RK | 1 |
| Poonia, B | 1 |
| Alm, JJ; Halkosaari, HJ; Heino, TJ; Välimäki, VV | 1 |
| Ando, T; Iwata, T; Kaibuchi, N; Okano, T; Yamato, M | 1 |
| Hao, X; Jing, D; Liu, J; Luo, E; Meng, G; Xu, F | 1 |
| Agacayak, KS; Deveci, E; Gülsün, B; Hamidi, A; Koparal, M | 1 |
| Amiaud, J; Battaglia, S; Charrier, C; Córdova, LA; Guilbaud, F; Heymann, D; Lezot, F; Piot, B; Redini, F | 1 |
| Baklaushev, VP; Burenkov, MS; Chekhonin, VP; Grinenko, NF; Gubskii, IL; Ivanova, NV; Rabinovich, EZ; Yusubalieva, GM | 1 |
| Egashira, K; Kawai, T; Kim, JY; Kiyama, T; Mawardi, H; Movila, A; Nishimura, K; Sasaki, H; Villa, A; Woo, SB | 1 |
| Artamonova, TD; Chefu, SG; Kolpakova, ME; Lisovskaya, EK; Vlasov, TD; Yagmurov, OD; Yaremenko, AI; Zubarevа, AA | 1 |
| Isaksson, H; Mathavan, N; Tägil, M | 1 |
| Gong, X; Sheng, Q; Su, J; Yu, W; Zhao, H | 1 |
| Gaitán-Cepeda, LA; Gómez-Clavel, JF; Vidal-Gutiérrez, X | 1 |
| Allocca, G; Brown, NJ; DeCristo, MJ; Haider, MT; Holen, I; McAllister, SS; Silver, DP; Ubellacker, JM | 1 |
| Gruenbaum, Y; Meshorer, E | 1 |
| Bouler, JM; Gauthier, O; Pioletti, DP; Stadelmann, VA; Terrier, A | 1 |
| Coleman, RE; Holen, I; Jones, M; Lefley, DV; Mönkkönen, H; Ottewell, PD | 1 |
| Anderson, KC; Lerman, MA; Lyng, GD; Sonis, ST; Watkins, BA | 1 |
| Atsu, N; Basaran, A; Basok, EK; Tokuc, R; Yildirim, A | 1 |
| Adachi, S; Fushiki, S; Horie, N; Kimura, S; Koto, K; Kubo, T; Maekawa, T; Matsui, T; Murata, H; Sakabe, T; Watanabe, M | 1 |
| Kyrgidis, A; Triaridis, S | 1 |
| Cho, SK; Lee, FY; Seo, SW; Storer, SK | 1 |
| Asuncion, F; Chiusaroli, R; Khatri, R; Kostenuik, P; Ohishi, M; Ominsky, M; Schipani, E; Thomas, C | 1 |
| Bakker, F; Baum, W; Burger, R; Gordon, S; Gramatzki, M; Green, JR; Guenther, A; Roelofs, AJ; Rogers, MJ; Tiemann, M | 1 |
| Allen, MR; Burr, DB | 1 |
| Jaatinen, J; Kröger, HP; Lappalainen, R; Miettinen, SS; Mönkkönen, J; Pelttari, A; Venesmaa, PK | 1 |
| Baas, J; Bechtold, JE; Elmengaard, B; Jakobsen, T; Søballe, K | 1 |
| Goto, H; Hanibuchi, M; Ikuta, K; Kakiuchi, S; Nishioka, Y; Ogino, H; Otsuka, S; Sone, S; Takahashi, T; Yamada, T; Yano, S | 1 |
| Bonfa, E; Caparbo, VF; Carvas, JS; Fuller, P; Lima, LA; Mello, SB; Pereira, RM; Silveira, CA | 1 |
| Cankaya, M; Ersoz, S; Gunhan, O; Kadioglu Duman, M; Muci, E; Pampu, AA; Senel, FC | 1 |
| Adams, JS; Christensen, R; Chung, EM; Felsenfeld, AL; Garrett, N; Hokugo, A; Nishimura, I; Sayre, JW; Sung, EC | 1 |
| Akiyama, K; Chen, C; Chen, W; Kikuiri, T; Kim, I; Le, AD; Li, Y; Shi, S; Wang, S; Yamaza, T; Zhang, Q | 1 |
| Biasotto, M; Cavalli, F; Chiandussi, S; Contardo, L; Di Lenarda, R; Dore, F; Giacca, M; Moimas, S; Pozzato, G; Zacchigna, S; Zanconati, F | 1 |
| Bonnet, N; Clézardin, P; Contié, S; Ferrari, S; Garnero, P; Litvin, J; Voorzanger-Rousselot, N | 1 |
| Azambuja, AA; Campos, MM; Cherubini, K; Maahs, MP; Salum, FG | 1 |
| Green, J; Lipton, A | 1 |
| Brennan, O; Kennedy, OD; Lee, TC; O'Brien, FJ; Rackard, SM | 1 |
| Lanigan, LG; Martin, CK; Rosol, TJ; Thudi, NK; Toribio, RE; Werbeck, JL; Wolfe, TD | 1 |
| Cai, D; Shi, WH; Wu, L; Yu, B; Zhu, L | 1 |
| Aykut, K; Gül, M; Güzeloğlu, M; Hazan, E; Reel, B; Yürekli, I | 1 |
| Green, JR; Guenther, A | 1 |
| Çelimli, N; Erdoğan, A; Ilgezdi, S; Ozkan, Y; Ozocak, E; Öztürk, A; Sahin, N; Yalçin, N | 1 |
| Baldock, PA; Birke, O; Little, DG; Morse, A; Ruys, A; Schindeler, A; Yu, NY | 1 |
| Doi, Y; Hara, K; Kataoka, M; Miyazaki, M; Tsumura, H; Yoshiiwa, T | 1 |
| Feng, G; Hu, J; Li, JH; Li, YF; Luo, E; Zhou, CC; Zhu, SS | 1 |
| Abdelsayed, RA; Borke, JL; Carter, JA; Elsalanty, M; Khashaba, RM; Marino, KL; O'Neill, JC; Stevens, MR; Zakhary, I | 1 |
| Brown, HK; Brown, NJ; Coleman, RE; Cross, SS; Holen, I; Jones, M; Ottewell, PD; Rogers, TL | 1 |
| Ashton, JM; Becker, MW; Calvi, LM; Frisch, BJ; Jordan, CT; Xing, L | 1 |
| Belt, BA; Gillanders, WE; Goedegebuure, P; Herndon, J; Hsieh, CS; Lee, HM; Linehan, DC; Mitchem, JB; Porembka, MR | 1 |
| Darendeliler, MA; Gonzales, C; Hashimoto, M; Hotokezaka, H; Luppanapornlarp, S; Sirisoontorn, I; Yoshida, N | 1 |
| Abdelkarim, M; Crepin, M; Di Benedetto, M; Jais, JP; Kassis, N; Lecouvey, M; Perret, GY; Vintonenko, N | 1 |
| Allen, MR; Brown, D; Carr, AJ; Chen, NX; Chen, X; Gattone, VH; LeBlanc, P; Moe, SM | 1 |
| Fan, M; Jiang, WX; Lu, SB; Peng, J; Wang, AY; Wang, Y; Xu, WJ; Zhang, L | 1 |
| Hashimoto, K; Hirata, K; Kitamura, H; Kobayashi, K; Maeda, T; Masumori, N; Tanaka, T; Tsukamoto, T | 1 |
| Baker, SP; Boskey, AL; Brooks, DJ; Burket, JC; MacLeay, JM; van der Meulen, MC | 1 |
| Li, Z; Sun, L; Tang, J; Ye, Z | 1 |
| Biskobing, DM; Downs, R; Novy, AM | 1 |
| Evans, GP; Glatt, M; Green, JR; Hornby, SB; Hornby, SL; Pataki, A | 1 |
| Hata, K; Hiraga, T; Ikeda, F; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T | 1 |
| Coleman, R; Croucher, P; Jagdev, S | 1 |
| Hiraga, T; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T | 1 |
| Baldock, PA; Eisman, JA; Gardiner, EM; Little, DG; McEvoy, A; Smith, EJ | 1 |
| Little, DG; McDonald, M; McEvoy, T; Peat, R; Sharpe, IT; Williams, P | 1 |
| Green, JR | 1 |
| Gouin, F; Heymann, D; Heymann, MF; Kamijo, A; Ory, B; Redini, F | 1 |
| Binnington, A; Cheung, R; Grynpas, MD; Kandel, RA; Kasra, M; Waldman, SD; White, LM; Wise, LM | 1 |
| Suzuki, M; Tomoo, T | 1 |
| Aldrich, W; Harris, KW; Merrell, MA; Millender-Swain, T; Selander, KS; Triozzi, P; Wakchoure, S | 1 |
| Duivenvoorden, WC; Kalina, M; Seidlitz, E; Singh, G; Vukmirović-Popović, S | 1 |
| Berger, SA; Bogoch, ER; Fornasier, VL; Lee, TC | 1 |
| Armstrong, A; Branstetter, D; Bussiere, J; Cowan, L; Dougall, WC; Jones, J; Kennedy, B; Miller, RE | 1 |
| Godfrey, C; Little, DG; McDonald, M; Mikulec, K; Morse, A; Ramachandran, M; Schindeler, A | 1 |
| Battaglia, S; Duteille, F; Gouin, F; Heymann, D; Heymann, MF; Lamoureux, F; Ory, B; Pilet, P; Redini, F | 1 |
| Allen, MJ; Arrington, SA; Damron, TA; Mann, KA | 1 |
| Bateman, TA; Lloyd, SA; Lu, T; Travis, ND | 1 |
| Brouwers, JE; Gasser, JA; Huiskes, R; Lambers, FM; van Rietbergen, B | 1 |
| Derese, I; Lories, RJ; Luyten, FP | 1 |
| Awad, HA; Bechtold, CD; Bukata, SV; Hock, C; Ito, H; Nakamura, T; O'Keefe, RJ; Proulx, ST; Schwarz, EM; Tsutsumi, R | 1 |
| Fernandez, SA; Martin, CK; Nadella, MV; Pinzone, JJ; Rosol, TJ; Thudi, NK; Werbeck, JL | 1 |
| Green, J | 1 |
| Grynpas, MD; Kandel, RA; Podworny, NV; Renlund, RC | 1 |
| Bogoch, ER; Moran, EL; Pysklywec, MW | 1 |
| Cooke-Yarborough, C; Little, DG; Smith, NC; Williams, PR | 1 |
7 review(s) available for zoledronic acid and Disease Models, Animal
| Article | Year |
|---|---|
Antineoplastic activity of zoledronic acid and denosumab.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials as Topic; Denosumab; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Neoplasms; Zoledronic Acid | 2013 |
Anticancer properties of zoledronic acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Cell Proliferation; Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Neoplasms; Zoledronic Acid | 2010 |
The backbone of progress--preclinical studies and innovations with zoledronic acid.
Topics: Animals; Apoptosis; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Imidazoles; Mice; Multiple Myeloma; Neovascularization, Pathologic; Osteoclasts; Zoledronic Acid | 2011 |
Novel therapeutic options for osteoporosis.
Topics: Animals; Controlled Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Evidence-Based Medicine; Fractures, Spontaneous; Glycoproteins; Humans; Ibandronic Acid; Imidazoles; Norpregnenes; Osteoporosis; Osteoprotegerin; Piperidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Selective Estrogen Receptor Modulators; Thiophenes; Zoledronic Acid | 2002 |
The anti-tumor potential of zoledronic acid.
Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Male; Mice; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Zoledronic Acid | 2003 |
Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Bone Density; Bone Diseases; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Male; Osteolysis; Prostatic Neoplasms; Tumor Burden; Zoledronic Acid | 2005 |
[Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Calcitriol; Cells, Cultured; Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Geranyltranstransferase; Humans; Hypercalcemia; Imidazoles; Neoplasms; Osteoclasts; Zoledronic Acid | 2005 |
1 trial(s) available for zoledronic acid and Disease Models, Animal
| Article | Year |
|---|---|
Nitrogen-containing bisphosphonate therapy-Part II: Assessment of alveolar bone tissue inflammatory response in rats-A blind randomized controlled trial.
Topics: Alveolar Process; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Remodeling; Diphosphonates; Disease Models, Animal; Inflammation; Male; Nitrogen; Osteonecrosis; Rats; Rats, Wistar; Tomography, X-Ray Computed; Zoledronic Acid | 2018 |
192 other study(ies) available for zoledronic acid and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Alveolar socket healing in 5-lipoxygenase knockout aged female mice treated or not with high dose of zoledronic acid.
Topics: Age Factors; Animals; Arachidonate 5-Lipoxygenase; Biomarkers; Disease Models, Animal; Female; Gene Expression; Immunohistochemistry; Mice; Mice, Knockout; Tooth Extraction; Tooth Socket; Treatment Outcome; Wound Healing; X-Ray Microtomography; Zoledronic Acid | 2021 |
Suppression of Bone Necrosis around Tooth Extraction Socket in a MRONJ-like Mouse Model by E-rhBMP-2 Containing Artificial Bone Graft Administration.
Topics: Alveolar Bone Loss; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Transplantation; Calcium Phosphates; Cyclophosphamide; Diphosphonates; Disease Models, Animal; Female; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Recombinant Proteins; Tooth Extraction; Transforming Growth Factor beta; Wound Healing; Zoledronic Acid | 2021 |
Combination treatment with growth hormone and zoledronic acid in a mouse model of Osteogenesis imperfecta.
Topics: Animals; Bone and Bones; Bone Density; Disease Models, Animal; Growth Hormone; Human Growth Hormone; Mice; Osteogenesis Imperfecta; Zoledronic Acid | 2022 |
Analysis of the effect of zoledronic acid on gene differences in rat jaw.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Hedgehog Proteins; Imidazoles; Rats; Rats, Sprague-Dawley; Zoledronic Acid | 2022 |
Computed Tomography-Based Investigation on the Effects of Intravenous Bisphosphonate Administration on Tooth Growth in a Minipig Animal Model.
Topics: Animals; Diphosphonates; Disease Models, Animal; Humans; Swine; Swine, Miniature; Tomography; Tomography, X-Ray Computed; Zoledronic Acid | 2022 |
Zoledronic acid generates a spatiotemporal effect to attenuate osteoarthritis by inhibiting potential Wnt5a-associated abnormal subchondral bone resorption.
Topics: Animals; Bone Resorption; Cartilage, Articular; Disease Models, Animal; Male; Osteoarthritis; Rats; Wnt-5a Protein; X-Ray Microtomography; Zoledronic Acid | 2022 |
Early zoledronate treatment inhibits subchondral bone microstructural changes in skeletally-mature, ACL-transected canine knees.
Topics: Animals; Anterior Cruciate Ligament Injuries; Bone and Bones; Cartilage, Articular; Disease Models, Animal; Dogs; Male; Meloxicam; Osteoarthritis; X-Ray Microtomography; Zoledronic Acid | 2023 |
Dietary nitrate improves jaw bone remodelling in zoledronate-treated mice.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Disease Models, Animal; Lipids; Mice; Nitrates; Zoledronic Acid | 2023 |
Effect of Periapical Diseases in Development of MRONJ in Immunocompromised Mouse Model.
Topics: Alveolar Bone Loss; Animals; Bone Density; Bone Density Conservation Agents; Dexamethasone; Disease Models, Animal; Female; Mandible; Mice; Mice, Inbred C57BL; Molar; Osteonecrosis; Ovariectomy; Periapical Diseases; X-Ray Microtomography; Zoledronic Acid | 2019 |
Endothelial Progenitor Cells inhibit jaw osteonecrosis in a rat model: A major adverse effect of bisphosphonate therapy.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell Proliferation; Cell Transplantation; Dexamethasone; Diphosphonates; Disease Models, Animal; Endothelial Progenitor Cells; Fibroblasts; Humans; Keratinocytes; Rats; Wound Healing; Zoledronic Acid | 2019 |
Extracellular Vesicles of Stem Cells to Prevent BRONJ.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Disease Models, Animal; Extracellular Vesicles; Mesenchymal Stem Cells; Rats; Zoledronic Acid | 2020 |
Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw.
Topics: Angiogenesis Inhibitors; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone and Bones; Bone Density Conservation Agents; Denosumab; Diphosphonates; Disease Models, Animal; Female; Fluvastatin; Osteonecrosis; Rats; Rats, Wistar; Tooth Extraction; Zoledronic Acid | 2020 |
Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.
Topics: Aging; Animals; Bone and Bones; Bone Density Conservation Agents; Cartilage; Disease Models, Animal; Femur; Glycosaminoglycans; Joints; Lamin Type A; Mice; Mice, Transgenic; Mutation; Osteoarthritis; Phenotype; Piperidines; Pravastatin; Progeria; Protein Processing, Post-Translational; Pyridines; X-Ray Microtomography; Zoledronic Acid | 2020 |
Modulation of spine fusion with BMP-2, MEK inhibitor (PD0325901), and zoledronic acid in a murine model of NF1 double inactivation.
Topics: Animals; Benzamides; Diphenylamine; Disease Models, Animal; Mice; Mitogen-Activated Protein Kinase Kinases; Neurofibromatosis 1; Zoledronic Acid | 2021 |
Implantable zoledronate-PLGA microcapsules ameliorate alveolar bone loss, gingival inflammation and oxidative stress in an experimental periodontitis rat model.
Topics: Alveolar Bone Loss; Animals; Antioxidants; Capsules; Catalase; Cytokines; Disease Models, Animal; Gingiva; Humans; Inflammation; Osteoprotegerin; Oxidative Stress; Polylactic Acid-Polyglycolic Acid Copolymer; Prosthesis Implantation; Rats; Superoxide Dismutase; Zoledronic Acid | 2021 |
Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw.
Topics: Animals; Apoptosis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell Transdifferentiation; Cytokine Release Syndrome; Cytokines; Disease Models, Animal; Female; Inflammation Mediators; Macrophages; Mice, Inbred C57BL; Models, Biological; Osteoclasts; Osteocytes; Osteogenesis; Porphyromonas gingivalis; Risk Factors; Tooth Extraction; Zoledronic Acid | 2021 |
Differential effects of anti-RANKL monoclonal antibody and zoledronic acid on necrotic bone in a murine model of Staphylococcus aureus-induced osteomyelitis.
Topics: Animals; Antibodies, Monoclonal; Bone Density Conservation Agents; Disease Models, Animal; Ligands; Mice; Osteoclasts; Osteolysis; Osteomyelitis; Osteonecrosis; RANK Ligand; Staphylococcal Infections; Staphylococcus aureus; X-Ray Microtomography; Zoledronic Acid | 2022 |
Zoledronic acid improves bone histomorphometry in a murine model of Rett syndrome.
Topics: Animals; Cancellous Bone; Cortical Bone; Diphosphonates; Disease Models, Animal; Imidazoles; Male; Methyl-CpG-Binding Protein 2; Mice; Mice, Inbred C57BL; Mice, Knockout; Rett Syndrome; X-Ray Microtomography; Zoledronic Acid | 2017 |
Zoledronate promotes bone formation by blocking osteocyte-osteoblast communication during bone defect healing.
Topics: Adaptor Proteins, Signal Transducing; Alkaline Phosphatase; Animals; Bone Density Conservation Agents; Cell Communication; Connexin 43; Diphosphonates; Disease Models, Animal; Extracellular Matrix Proteins; Femoral Fractures; Fracture Healing; Glycoproteins; Imidazoles; Intercellular Signaling Peptides and Proteins; Male; Mice; Osteoblasts; Osteoclasts; Osteocytes; Osteogenesis; Signal Transduction; Tartrate-Resistant Acid Phosphatase; Time Factors; Zoledronic Acid | 2018 |
Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies; Bone Density; Diphosphonates; Disease Models, Animal; Female; Glycoproteins; Imidazoles; Intercellular Signaling Peptides and Proteins; Mice; Osteogenesis; Osteogenesis Imperfecta; Zoledronic Acid | 2017 |
Early bony changes associated with bisphosphonate-related osteonecrosis of the jaws in rats: A longitudinal in vivo study.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Disease Models, Animal; Imidazoles; Longitudinal Studies; Molar; Rats; Tooth Extraction; X-Ray Microtomography; Zoledronic Acid | 2017 |
Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism.
Topics: Animals; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Imidazoles; Mice; Mice, Knockout; Nuclear Matrix-Associated Proteins; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Transcription Factors; Zoledronic Acid | 2017 |
Improved union and bone strength in a mouse model of NF1 pseudarthrosis treated with recombinant human bone morphogenetic protein-2 and zoledronic acid.
Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bony Callus; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Genes, Neurofibromatosis 1; Mice; Neurofibromatosis 1; Pseudarthrosis; Recombinant Proteins; Transforming Growth Factor beta; Zoledronic Acid | 2018 |
Further development of the MRONJ minipig large animal model.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Jaw; Radiography; Random Allocation; Reproducibility of Results; Swine; Swine, Miniature; Tooth Extraction; Zoledronic Acid | 2017 |
Safety and efficacy of hydroxyapatite scaffold in the prevention of jaw osteonecrosis in vivo.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Disease Models, Animal; Durapatite; Male; Rats; Rats, Wistar; Tissue Scaffolds; Tooth Extraction; Zoledronic Acid | 2018 |
Local effect of zoledronic acid on new bone formation in posterolateral spinal fusion with demineralized bone matrix in a murine model.
Topics: Animals; Biocompatible Materials; Bone Density Conservation Agents; Bone Matrix; Bone Transplantation; Diphosphonates; Disease Models, Animal; Imidazoles; Mice; Osteogenesis; Spinal Fusion; Spine; X-Ray Microtomography; Zoledronic Acid | 2018 |
Evaluation of mandibular fracture healing in rats under zoledronate therapy: A histologic study.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bony Callus; Diphosphonates; Disease Models, Animal; Fracture Healing; Imidazoles; Male; Mandibular Fractures; Osteoclasts; Rats; Rats, Wistar; Zoledronic Acid | 2017 |
Evaluation of the bisphosphonate effect on stem cells derived from jaw bone and long bone rabbit models: A pilot study.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cell Proliferation; Cell Survival; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Mandible; Mesenchymal Stem Cells; Pilot Projects; Rabbits; Tibia; Zoledronic Acid | 2018 |
Role of Periapical Diseases in Medication-Related Osteonecrosis of the Jaws.
Topics: Alveolar Bone Loss; Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Jaw; Mandible; Mice; Molar; Necrosis; Osteocytes; Osteonecrosis; Periapical Diseases; Tomography, X-Ray Computed; Zoledronic Acid | 2017 |
Bis‑enoxacin blocks alveolar bone resorption in rats with ovariectomy‑induced osteoporosis.
Topics: Alveolar Bone Loss; Animals; Body Weight; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Enoxacin; Female; Imidazoles; Microscopy, Fluorescence; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; X-Ray Microtomography; Zoledronic Acid | 2018 |
Longitudinal resting-state functional magnetic resonance imaging in a mouse model of metastatic bone cancer reveals distinct functional reorganizations along a developing chronic pain state.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chronic Pain; Disease Models, Animal; Female; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Oxygen; Pain Measurement; Rest; Zoledronic Acid | 2018 |
The compositional and nano-structural basis of fracture healing in healthy and osteoporotic bone.
Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 7; Bony Callus; Diphosphonates; Disease Models, Animal; Fracture Healing; Fractures, Bone; Imidazoles; Osteoporosis; Rats; Scattering, Small Angle; Spectroscopy, Fourier Transform Infrared; Zoledronic Acid | 2018 |
Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Drug Synergism; Estradiol; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Gene Expression; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Mice; Models, Biological; Signal Transduction; Xenograft Model Antitumor Assays; Zoledronic Acid | 2018 |
Beneficial Therapeutic Effects of Sildenafil on Bone Healing in Animals Treated with Bisphosphonate.
Topics: Animals; Biopsy; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fracture Healing; Imidazoles; Mandibular Fractures; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Zoledronic Acid | 2018 |
Negative effect of zoledronic acid on tendon-to-bone healing.
Topics: Achilles Tendon; Animals; Bone Density Conservation Agents; Bone Remodeling; Disease Models, Animal; Female; Rats; Rats, Wistar; Tendon Injuries; Tenodesis; Wound Healing; Zoledronic Acid | 2018 |
Inhibition of Aortic Valve Calcification by Local Delivery of Zoledronic Acid-an Experimental Study.
Topics: Angioplasty, Balloon, Coronary; Animals; Aortic Valve; Aortic Valve Stenosis; Bone Density Conservation Agents; Calcinosis; Cardiac Catheters; Disease Models, Animal; Drug Delivery Systems; Echocardiography; Male; Positron Emission Tomography Computed Tomography; Rabbits; Time Factors; Zoledronic Acid | 2018 |
Anti-mouse RANKL Antibodies Inhibit Alveolar Bone Destruction in Periodontitis Model Mice.
Topics: Alveolar Bone Loss; Animals; Antibodies; Diphosphonates; Disease Models, Animal; Imidazoles; Lipopolysaccharides; Male; Mice, Inbred C57BL; Osteoclasts; Periodontitis; RANK Ligand; Skull; Zoledronic Acid | 2018 |
PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Programmed Cell Death 1 Receptor; Zoledronic Acid | 2018 |
Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Disease Models, Animal; Male; Optical Imaging; Rats, Inbred Strains; Renal Insufficiency, Chronic; Tibia; Zoledronic Acid | 2018 |
Does zoledronate therapy make mandibular bone susceptible to fracture? A radiographical and biomechanical study in rats.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Disease Models, Animal; Male; Mandible; Mandibular Fractures; Random Allocation; Rats; Rats, Wistar; Stress, Mechanical; Zoledronic Acid | 2018 |
Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62
Topics: Aging; Animals; Bone and Bones; Bone Resorption; Calcification, Physiologic; Disease Models, Animal; Mice, Inbred C57BL; Mice, Mutant Strains; Mutation; Organ Size; Osteitis Deformans; Osteoclasts; Phenotype; Sequestosome-1 Protein; Zoledronic Acid | 2018 |
Combination therapy with low-dose teriparatide and zoledronate contributes to fracture healing on rat femoral fracture model.
Topics: Animals; Bone Density Conservation Agents; Bony Callus; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Femoral Fractures; Fracture Healing; Male; Radiography; Rats, Sprague-Dawley; Teriparatide; Zoledronic Acid | 2018 |
Circulating microRNA Panel as a Novel Biomarker to Diagnose Bisphosphonate-Related Osteonecrosis of the Jaw.
Topics: Animals; Biomarkers; Bisphosphonate-Associated Osteonecrosis of the Jaw; Circulating MicroRNA; Disease Models, Animal; Female; Humans; Oligonucleotide Array Sequence Analysis; Osteoporosis; Predictive Value of Tests; Prognosis; Rats; Rats, Sprague-Dawley; Zoledronic Acid | 2018 |
Mesoporous bioactive glass/ɛ-polycaprolactone scaffolds promote bone regeneration in osteoporotic sheep.
Topics: Animals; Bone Regeneration; Disease Models, Animal; Drug Implants; Female; Glass; Humans; Mice; Osteoblasts; Osteoclasts; Osteogenesis; Osteoporosis; Polyesters; Porosity; RAW 264.7 Cells; Sheep; Zoledronic Acid | 2019 |
Systemic sclerostin antibody treatment increases osseointegration and biomechanical competence of zoledronic-acid-coated dental implants in a rat osteoporosis model.
Topics: Animals; Antibodies; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Coated Materials, Biocompatible; Dental Implants; Disease Models, Animal; Female; Genetic Markers; Osseointegration; Osteoporosis; Rats; Rats, Wistar; Zoledronic Acid | 2019 |
Adipose-derived stem cells prevent the onset of bisphosphonate-related osteonecrosis of the jaw through transforming growth factor β-1-mediated gingival wound healing.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Disease Models, Animal; Fibronectins; Gene Expression Regulation, Developmental; Gingiva; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Rabbits; Transforming Growth Factor beta1; Wound Healing; Zoledronic Acid | 2019 |
Medication-related osteonecrosis of the jaws after tooth extraction in senescent female mice treated with zoledronic acid: Microtomographic, histological and immunohistochemical characterization.
Topics: Aging; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Calcification, Physiologic; Collagen; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Female; Mice; Tooth Extraction; Transforming Growth Factor beta; X-Ray Microtomography; Zoledronic Acid | 2019 |
Systemic administration of quality- and quantity-controlled PBMNCs reduces bisphosphonate-related osteonecrosis of jaw-like lesions in mice.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cyclophosphamide; Disease Models, Animal; Humans; Leukocytes, Mononuclear; Macrophages; Mice; Molar; Peripheral Blood Stem Cell Transplantation; Tooth Extraction; Wound Healing; X-Ray Microtomography; Zoledronic Acid | 2019 |
Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Imidazoles; Male; Mandible; Mice; Molar; Periapical Diseases; Periosteum; Rats; Zoledronic Acid | 2013 |
The effect of bone morphometric changes on orthodontic tooth movement in an osteoporotic animal model.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Tibia; Tooth Movement Techniques; X-Ray Microtomography; Zoledronic Acid | 2013 |
Allogeneic mesenchymal stem cell therapy for bisphosphonate-related jaw osteonecrosis in Swine.
Topics: Animals; Biomarkers; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Disease Models, Animal; Female; Forkhead Transcription Factors; Humans; Imidazoles; Interleukin-17; Male; Mandible; Mesenchymal Stem Cell Transplantation; Radiography; Swine; Swine, Miniature; T-Lymphocytes, Regulatory; Transplantation, Homologous; Zoledronic Acid | 2013 |
Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.
Topics: Adoptive Transfer; Animals; Apoptosis; Cell Line, Tumor; Chemokine CXCL10; Combined Modality Therapy; Cytotoxicity, Immunologic; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Immunophenotyping; Interferon-gamma; Lymphocytes, Tumor-Infiltrating; Mice; Neovascularization, Pathologic; Neuroblastoma; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Treatment Outcome; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid | 2013 |
Short-term effect of zoledronic acid upon fracture resistance of the mandibular condyle and femoral head in an animal model.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Femur Head; Hip Fractures; Imidazoles; Male; Mandibular Condyle; Mandibular Fractures; Rats; Rats, Sprague-Dawley; Time Factors; Zoledronic Acid | 2013 |
IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Interleukin-17; Jaw; Macrophages; Mice; Neoplasms; Zoledronic Acid | 2013 |
Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.
Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cat Diseases; Cats; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diphosphonates; Disease Models, Animal; Heterografts; Humans; Imidazoles; Male; Meloxicam; Mice; Mice, Nude; Mouth Neoplasms; Neoplasms, Squamous Cell; Random Allocation; Real-Time Polymerase Chain Reaction; RNA, Messenger; Thiazines; Thiazoles; Treatment Outcome; Zoledronic Acid | 2015 |
Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cachexia; Cell Proliferation; Diphosphonates; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA, Neoplasm; Doxorubicin; Female; Imidazoles; Kaplan-Meier Estimate; Mice; Osteoblasts; Osteoclasts; Radioisotopes; Radium; Stem Cells; Tumor Cells, Cultured; Zoledronic Acid | 2013 |
Osteoprotegerin reduces the development of pain behaviour and joint pathology in a model of osteoarthritis.
Topics: Animals; Arthralgia; Behavior, Animal; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Imidazoles; Iodoacetic Acid; Joints; Male; Nociceptors; Osteoarthritis; Osteoclasts; Osteophyte; Osteoprotegerin; Rats; Rats, Sprague-Dawley; Spinal Cord; Zoledronic Acid | 2014 |
The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Jaw Diseases; Mandible; Osteogenesis; Osteoporosis; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Tooth Extraction; Zoledronic Acid | 2013 |
Osseointegration of biochemically modified implants in an osteoporosis rodent model.
Topics: Animals; Biomechanical Phenomena; Diphosphonates; Disease Models, Animal; Female; Fluorescent Dyes; Imidazoles; Implants, Experimental; Osseointegration; Osteoporosis; Rats; Rats, Wistar; Simvastatin; X-Ray Microtomography; Zoledronic Acid | 2013 |
The effects of zoledronic acid on mandibular fracture healing in an osteoporotic model: a stereological study.
Topics: Animals; Bone Density Conservation Agents; Bone Plates; Diphosphonates; Disease Models, Animal; Female; Fracture Healing; Imidazoles; Mandible; Mandibular Fractures; Osteogenesis; Osteoporosis; Ovariectomy; Random Allocation; Rats; Rats, Sprague-Dawley; Time Factors; Zoledronic Acid | 2013 |
Bacterial promotion of bisphosphonate-induced osteonecrosis in Wistar rats.
Topics: Aggregatibacter actinomycetemcomitans; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Marrow; Diphosphonates; Disease Models, Animal; Femur; Imidazoles; Male; Mandible; Pasteurellaceae Infections; Rats; Rats, Wistar; Zoledronic Acid | 2013 |
A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Calcium; Cardiovascular System; Diphosphonates; Disease Models, Animal; Imidazoles; Kidney Failure, Chronic; Rats; X-Ray Microtomography; Zoledronic Acid | 2014 |
Manipulation of anabolic and catabolic responses with bone morphogenetic protein and zoledronic acid in a rat spinal fusion model.
Topics: Animals; Bone Morphogenetic Protein 2; Diphosphonates; Disease Models, Animal; Humans; Imaging, Three-Dimensional; Imidazoles; Male; Osteoclasts; Palpation; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Spinal Fusion; Spine; Transforming Growth Factor beta; X-Ray Microtomography; Zoledronic Acid | 2014 |
Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model.
Topics: Acid Phosphatase; Alveolar Process; Animals; Apoptosis; Biomarkers; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Bone Marrow; Cell Adhesion; Cell Count; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Injections, Intraperitoneal; Injections, Subcutaneous; Isoenzymes; Molar; Osteoclasts; Osteogenesis; Random Allocation; Rats; Rats, Sprague-Dawley; Tartrate-Resistant Acid Phosphatase; Teriparatide; Tooth Extraction; Tooth Socket; X-Ray Microtomography; Zoledronic Acid | 2014 |
Sequential treatment with monofluorophosphate and zoledronic acid in osteoporotic rats.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium, Dietary; Diphosphonates; Disease Models, Animal; Female; Fluorides; Imidazoles; Osteoporosis; Osteoporotic Fractures; Ovariectomy; Phosphates; Rats; Rats, Sprague-Dawley; Treatment Outcome; Zoledronic Acid | 2014 |
Zoledronate attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of Rho/ROCK-dependent JNK and NF-κB pathway.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Cell Adhesion; Cell Line; Coculture Techniques; Dilatation, Pathologic; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Elastin; Endothelial Cells; Enzyme Activation; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Macrophages; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; NF-kappa B; Phosphorylation; Receptors, LDL; rho GTP-Binding Proteins; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Vascular Cell Adhesion Molecule-1; Zoledronic Acid | 2013 |
Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment.
Topics: Animals; Bone Diseases; C-Reactive Protein; Calcium; Dental Cementum; Dental Enamel; Diphosphonates; Disease Models, Animal; Heterozygote; Imidazoles; Inflammation; Kidney Diseases; Male; Mandible; Parathyroid Hormone; Periodontitis; Phenotype; Rats; Tomography, X-Ray Computed; X-Ray Microtomography; Zoledronic Acid | 2013 |
Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats.
Topics: Abscess; Alveolar Process; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Models, Animal; Imidazoles; Injections, Intraperitoneal; Injections, Intravenous; Male; Maxilla; Molar; Osteoclasts; Osteosclerosis; Random Allocation; Rats; Rats, Wistar; Tooth Extraction; Zoledronic Acid | 2014 |
Protective effect of zoledronic acid on corticosteroid-induced chondrocyte apoptosis in rat articular cartilage.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Cartilage, Articular; Chondrocytes; Diphosphonates; Disease Models, Animal; Imidazoles; Rats; Rats, Wistar; Zoledronic Acid | 2013 |
Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Diphosphonates; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Sarcoma, Ewing; Tumor Burden; Tumor Cells, Cultured; Zoledronic Acid | 2014 |
Intra-articular zoledronic acid in a rat osteoarthritis model: significant reduced synovitis may indicate chondroprotective effect.
Topics: Animals; Bone Density Conservation Agents; Cartilage, Articular; Chondrocytes; Diphosphonates; Disease Models, Animal; Disease Progression; Imidazoles; Injections, Intra-Articular; Male; Osteoarthritis, Knee; Rats; Rats, Wistar; Synovial Membrane; Synovitis; Zoledronic Acid | 2015 |
Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hydroxycholecalciferols; Imidazoles; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Wistar; Zoledronic Acid | 2014 |
Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cellular Microenvironment; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Osteoclasts; Ovariectomy; Postmenopause; Premenopause; Real-Time Polymerase Chain Reaction; X-Ray Microtomography; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |
Immunohistochemical expression of caspase-3, caspase-5, caspase-7 and apoptotic protease-activating factor-1 (APAF-1) in the liver and kidney of rats exposed to zoledronic acid (ZOL) and basic fibroblast growth factor (bFGF).
Topics: Animals; Apoptosis; Apoptotic Protease-Activating Factor 1; Bone Density Conservation Agents; Caspase 3; Caspase 7; Caspases; Diphosphonates; Disease Models, Animal; Fibroblast Growth Factors; Imidazoles; Immunohistochemistry; Kidney; Liver; Random Allocation; Rats; Rats, Sprague-Dawley; Zoledronic Acid | 2014 |
Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Topics: Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Green Fluorescent Proteins; Humans; Imidazoles; Immunocompromised Host; Mice, Inbred BALB C; Mice, Nude; Organ Size; Osteoblasts; Osteoclasts; Reproducibility of Results; Zoledronic Acid | 2014 |
Fluorescence-guided surgery of prostate cancer bone metastasis.
Topics: Adenocarcinoma; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Disease-Free Survival; Green Fluorescent Proteins; Humans; Imidazoles; Luminescent Proteins; Lymphatic Metastasis; Male; Mice, Nude; Neoplasm Recurrence, Local; Neoplasm, Residual; Optical Imaging; Prostatic Neoplasms; Red Fluorescent Protein; Zoledronic Acid | 2014 |
Assessing treatment response of osteolytic lesions by manual volumetry, automatic segmentation, and RECIST in experimental bone metastases.
Topics: Algorithms; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cone-Beam Computed Tomography; Diphosphonates; Disease Models, Animal; Follow-Up Studies; Imidazoles; Indoles; Pyrroles; Radiographic Image Interpretation, Computer-Assisted; Rats; Rats, Nude; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Zoledronic Acid | 2014 |
Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.
Topics: Acid Phosphatase; Alveolar Process; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Resorption; Diphosphonates; Disease Models, Animal; Imidazoles; Isoenzymes; Male; Maxilla; Mice, Inbred C57BL; Periodontium; Radiography; Recombinant Fusion Proteins; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2014 |
The tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid.
Topics: Animals; Cell Communication; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Models, Animal; Disease Progression; Heterografts; Humans; Imidazoles; Macrophages; Mice; Mitosis; Pancreatic Neoplasms; Zoledronic Acid | 2014 |
Chondroprotective effect of high-dose zoledronic acid: An experimental study in a rabbit model of osteoarthritis.
Topics: Animals; Bone Density Conservation Agents; Chondrocytes; Diphosphonates; Disease Models, Animal; Imidazoles; Male; Osteoarthritis; Rabbits; Zoledronic Acid | 2014 |
Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-κB ligand antibody in mice.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Resorption; Denosumab; Diphosphonates; Disease Models, Animal; Imidazoles; Mice; Osteoclasts; RANK Ligand; Zoledronic Acid | 2014 |
Periosteal microcirculatory reactions in a zoledronate-induced osteonecrosis model of the jaw in rats.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Imidazoles; Mandible; Microcirculation; Microscopy, Fluorescence; Periosteum; Rats; Rats, Sprague-Dawley; Tooth Extraction; X-Ray Microtomography; Zoledronic Acid | 2015 |
The effects of bisphosphonate on the remodeling of different irregular bones in mice.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Remodeling; Calcium-Binding Proteins; Dexamethasone; Diphosphonates; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Extracellular Matrix Proteins; Female; Ilium; Imidazoles; Immunohistochemistry; Interleukin-17; Jaw; Maxilla; Mice; Mice, Inbred C57BL; RANK Ligand; Zoledronic Acid | 2015 |
Role of periodontal disease in bisphosphonate-related osteonecrosis of the jaws in ovariectomized rats.
Topics: Alveolar Bone Loss; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Disease Models, Animal; Disease Progression; Female; Imidazoles; Ovariectomy; Periodontal Diseases; Random Allocation; Rats; Rats, Sprague-Dawley; X-Ray Microtomography; Zoledronic Acid | 2016 |
Evaluation of the therapeutic effects of conditioned media from mesenchymal stem cells in a rat bisphosphonate-related osteonecrosis of the jaw-like model.
Topics: Animals; Apoptosis; Biomarkers; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cell Differentiation; Cell Survival; Culture Media, Conditioned; Dexamethasone; Diphosphonates; Disease Models, Animal; Gene Expression Regulation; Humans; Imidazoles; Injections; Intercellular Signaling Peptides and Proteins; Male; Mesenchymal Stem Cells; Neovascularization, Physiologic; Osteoclasts; Osteogenesis; Radiography; Rats, Wistar; Real-Time Polymerase Chain Reaction; Zoledronic Acid | 2015 |
OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
Topics: Abscess; Acid Phosphatase; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Resorption; Denosumab; Diphosphonates; Disease Models, Animal; Imidazoles; Immunoglobulin Fc Fragments; Isoenzymes; Male; Mandible; Maxilla; Mice; Mice, Inbred C57BL; Osteoclasts; Osteoprotegerin; RANK Ligand; Rats; Recombinant Fusion Proteins; Tartrate-Resistant Acid Phosphatase; X-Ray Microtomography; Zoledronic Acid | 2015 |
NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
Topics: Animals; Bone and Bones; Bone Diseases; Bone Marrow; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Multiple Myeloma; Neoplasm Transplantation; Oligopeptides; Tumor Cells, Cultured; Zoledronic Acid | 2015 |
Zoledronate induces bisphosphonate-related osteonecrosis of the jaw in osteopenic sheep.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Diseases, Metabolic; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Ovariectomy; Random Allocation; Sheep, Domestic; Tooth Extraction; Wound Healing; Zoledronic Acid | 2016 |
Effect of zoledronic acid on spinal fusion outcomes in an ovariectomized rat model of osteoporosis.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Lumbar Vertebrae; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Spinal Fusion; X-Ray Microtomography; Zoledronic Acid | 2015 |
Osteonecrosis of the Jaw Developed in Mice: DISEASE VARIANTS REGULATED BY γδ T CELLS IN ORAL MUCOSAL BARRIER IMMUNITY.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; DNA-Binding Proteins; Female; Humans; Imidazoles; Immunity, Mucosal; In Vitro Techniques; Jaw; Mice; Mice, Inbred C57BL; Mice, Knockout; Mouth Mucosa; Osteoclasts; Receptors, Antigen, T-Cell, gamma-delta; Risk Factors; T-Lymphocyte Subsets; Tooth Extraction; Wound Healing; X-Ray Microtomography; Zoledronic Acid | 2015 |
Adipose-derived stem cells and platelet-rich plasma for preventive treatment of bisphosphonate-related osteonecrosis of the jaw in a murine model.
Topics: Adipocytes; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Imidazoles; Male; Platelet-Rich Plasma; Rats; Rats, Wistar; Stem Cells; Zoledronic Acid | 2015 |
Effect of different doses of zoledronic acid in establishing of bisphosphonate-related osteonecrosis.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Imidazoles; Kidney; Liver; Male; Radiography; Rats; Rats, Wistar; Spleen; Stomach; Zoledronic Acid | 2015 |
The inhibitory effect of zoledronate on early-stage osteoinduction by recombinant human bone morphogenetic protein 2 in an osteoporosis model.
Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Remodeling; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Osteogenesis; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Skull; Transforming Growth Factor beta; Wound Healing; X-Ray Microtomography; Zoledronic Acid | 2015 |
Nitrogen-containing bisphosphonate therapy: assessment of the alveolar bone structure in rats - a blind randomized controlled trial.
Topics: Alveolar Process; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Imidazoles; Male; Rats; Rats, Wistar; Tomography, X-Ray Computed; Tooth Extraction; Zoledronic Acid | 2015 |
Assessment of the Impact of Zoledronic Acid on Ovariectomized Osteoporosis Model Using Micro-CT Scanning.
Topics: Animals; Diphosphonates; Disease Models, Animal; Estradiol; Female; Humans; Imidazoles; Mice; Osteoporosis, Postmenopausal; Ovariectomy; X-Ray Microtomography; Zoledronic Acid | 2015 |
Zoledronate induces osteonecrosis of the jaw in sheep.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Imidazoles; Jaw; Sheep; Zoledronic Acid | 2015 |
A Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major Trauma.
Topics: Acid Phosphatase; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Isoenzymes; Kidney; Liver; Mandible; Osteoclasts; Rats, Sprague-Dawley; Tartrate-Resistant Acid Phosphatase; Tooth Extraction; Wound Healing; Wounds and Injuries; X-Ray Microtomography; Zoledronic Acid | 2015 |
A novel model of bisphosphonate-related osteonecrosis of the jaw in rats.
Topics: Animals; Biomarkers; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Maxilla; Osteoprotegerin; RANK Ligand; Rats, Sprague-Dawley; Time Factors; Wound Healing; Zoledronic Acid | 2015 |
Histopathological Effects of Teriparatide in Medication-Related Osteonecrosis of the Jaw: An Animal Study.
Topics: Animals; Anti-Inflammatory Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell Count; Dexamethasone; Diphosphonates; Disease Models, Animal; Imidazoles; Inflammation; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Molar; Osteoblasts; Osteoclasts; Rats; Rats, Wistar; Teriparatide; Tooth Extraction; Wound Healing; Zoledronic Acid | 2016 |
[Effect of thalidomide on development of bisphosphonate-related osteonecrosis of the jaws in rats].
Topics: Animals; Apoptosis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Diphosphonates; Disease Models, Animal; Imidazoles; Molar; Neovascularization, Physiologic; Rats; Thalidomide; Tooth Extraction; Zoledronic Acid | 2015 |
Impact of Actinomyces naeslundii on bisphosphonate-related osteonecrosis of the jaws in ovariectomized rats with periodontitis.
Topics: Actinomyces; Actinomycosis; Alveolar Bone Loss; Animals; Bacterial Load; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Cancellous Bone; Diphosphonates; Disease Models, Animal; Disease Progression; Female; Imidazoles; Mandibular Diseases; Ovariectomy; Periodontitis; Random Allocation; Rats; Rats, Sprague-Dawley; X-Ray Microtomography; Zoledronic Acid | 2015 |
Animal model for medication-related osteonecrosis of the jaw with precedent metabolic bone disease.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Osteoclasts; Osteoporosis; Ovariectomy; Random Allocation; Rats; Rats, Sprague-Dawley; Tooth; X-Ray Microtomography; Zoledronic Acid | 2015 |
Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease.
Topics: Anemia, Sickle Cell; Animals; Bone Diseases; Cathepsin K; Core Binding Factor Alpha 1 Subunit; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Interleukin-6; Mice; Mice, Transgenic; Osteoclasts; Osteonectin; RANK Ligand; Reperfusion Injury; Zoledronic Acid | 2015 |
Perioperative discontinuation of intravenous bisphosphonate therapy reduces the incidence and severity of bisphosphonate-related osteonecrosis of the jaw: A randomized, controlled, prospective experimental study in rats.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Drug Administration Schedule; Imidazoles; Injections, Intravenous; Osteogenesis; Perioperative Period; Prospective Studies; Random Allocation; Rats, Wistar; Risk Factors; Tooth Extraction; Withholding Treatment; Wound Healing; Zoledronic Acid | 2015 |
Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Diphosphonates; Disease Models, Animal; ErbB Receptors; Gene Expression; Humans; Imidazoles; Male; ras Proteins; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
Pharmacokinetic and therapeutic efficacy of intrapulmonary administration of zoledronate for the prevention of bone destruction in rheumatoid arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone and Bones; Bone Density Conservation Agents; Bronchoalveolar Lavage Fluid; Collagen; Creatinine; Diphosphonates; Disease Models, Animal; Drug Delivery Systems; Imidazoles; Lung; Male; Mice; Mice, Inbred DBA; Rats; Rats, Wistar; Zoledronic Acid | 2016 |
Effect of antiresorptive and anabolic bone therapy on development of osteoarthritis in a posttraumatic rat model of OA.
Topics: Animals; Bone Density Conservation Agents; Cartilage, Articular; Chondrocytes; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Male; Osteoarthritis; Parathyroid Hormone; Rats; Rats, Inbred Lew; X-Ray Microtomography; Zoledronic Acid | 2015 |
In vitro and in vivo investigation of bisphosphonate-loaded hydroxyapatite particles for peri-implant bone augmentation.
Topics: Animals; Bone Substitutes; Diphosphonates; Disease Models, Animal; Durapatite; Female; Femur; Humans; Imidazoles; Mice; Osteoporosis, Postmenopausal; Rats; Rats, Wistar; RAW 264.7 Cells; Zoledronic Acid | 2017 |
Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Diphosphonates; Disease Models, Animal; Female; Hemiterpenes; Humans; Hyperthermia, Induced; Imidazoles; Organophosphorus Compounds; rap1 GTP-Binding Proteins; Ultrasonic Waves; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Establishment of an Animal Model of Bisphosphonate-Related Osteonecrosis of the Jaws in Spontaneously Diabetic Torii Rats.
Topics: Acid Phosphatase; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Remodeling; Diabetes Mellitus, Type 2; Diphosphonates; Disease Models, Animal; Gene Expression; Humans; Imidazoles; Injections, Intravenous; Isoenzymes; Male; Maxilla; Molar; Osteoclasts; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Tartrate-Resistant Acid Phosphatase; Tooth Extraction; Zoledronic Acid | 2015 |
Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Jaw Diseases; Microscopy, Electron, Scanning; Ovariectomy; Random Allocation; Rats; Rats, Sprague-Dawley; Risk Factors; Zoledronic Acid | 2016 |
Evaluation of BP-ONJ in osteopenic and healthy sheep: comparing ZTE-MRI with µCT.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Glucocorticoids; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Imidazoles; Magnetic Resonance Imaging; Mandibular Diseases; Ovariectomy; Periosteum; Random Allocation; Sheep; Tooth Socket; X-Ray Microtomography; Zoledronic Acid | 2016 |
Histopathological features of bisphosphonates related osteonecrosis of the jaw in rats with and without vitamin d supplementation.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Disease Models, Animal; Imidazoles; Jaw; Male; Maxilla; Orthognathic Surgical Procedures; Osteoblasts; Osteoclasts; Osteonecrosis; Rats; Rats, Wistar; Tooth Extraction; Vitamin D; Zoledronic Acid | 2016 |
Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
Topics: Adenine Nucleotides; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Drug Synergism; Female; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthoquinones; Osteoclasts; Osteolysis; Phosphorylation; Random Allocation; Signal Transduction; Zoledronic Acid | 2016 |
Guided bone regeneration in osteoporotic conditions following treatment with zoledronic acid.
Topics: Animals; Bone Density Conservation Agents; Bone Regeneration; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Osteoporosis; Ovariectomy; Parietal Bone; Rats, Wistar; Zoledronic Acid | 2017 |
Adoptive transfer of aminobisphonate-expanded Vγ9Vδ2+ T cells does not control HIV replication in a humanized mouse model.
Topics: Adoptive Transfer; Animals; Antibodies, Monoclonal; CD4-Positive T-Lymphocytes; Cell Proliferation; Diphosphonates; Disease Models, Animal; HIV Core Protein p24; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Imidazoles; Mice; Mice, Inbred NOD; Mice, SCID; Receptors, Antigen, T-Cell, gamma-delta; Receptors, CCR5; Viremia; Virus Replication; Zoledronic Acid | 2016 |
Zoledronic acid in vivo increases in vitro proliferation of rat mesenchymal stromal cells.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Cell Differentiation; Cell Proliferation; Cells, Cultured; Diphosphonates; Disease Models, Animal; Female; Femoral Fractures; Imidazoles; Mesenchymal Stem Cells; Rats; X-Ray Microtomography; Zoledronic Acid | 2016 |
Multipotent mesenchymal stromal cell sheet therapy for bisphosphonate-related osteonecrosis of the jaw in a rat model.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cell Differentiation; Cell Survival; Colony-Forming Units Assay; Dexamethasone; Diphosphonates; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Green Fluorescent Proteins; Imidazoles; Immunohistochemistry; Injections, Intravenous; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Multipotent Stem Cells; Rats, Sprague-Dawley; Transplantation, Homologous; Zoledronic Acid | 2016 |
Effects of local delivery of BMP2, zoledronate and their combination on bone microarchitecture, biomechanics and bone turnover in osteoporotic rabbits.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Remodeling; Diphosphonates; Disease Models, Animal; Drug Delivery Systems; Female; Femur Neck; Fibrin Tissue Adhesive; Imidazoles; Osteoporosis; Ovariectomy; Rabbits; Recombinant Proteins; X-Ray Microtomography; Zoledronic Acid | 2016 |
Effect of Zoledronic Acid Application on Different Graft Materials in Calvarial Bone Defect Models. An Experimental Analysis.
Topics: Administration, Intravenous; Animals; Bone Density Conservation Agents; Bone Substitutes; Bone Transplantation; Diphosphonates; Disease Models, Animal; Drug Administration Schedule; Heterografts; Imidazoles; Male; Osseointegration; Osteogenesis; Rats, Sprague-Dawley; Skull; Time Factors; Zoledronic Acid | 2016 |
Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell Differentiation; Diphosphonates; Disease Models, Animal; Imidazoles; Male; Mice; Mice, Inbred C57BL; Molar; Osteoblasts; Tooth Extraction; Tooth Socket; X-Ray Microtomography; Zoledronic Acid | 2016 |
Mono- and Combined Therapy of Metastasizing Breast Carcinoma 4T1 with Zoledronic Acid and Doxorubicin.
Topics: Animals; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Doxorubicin; Female; Imidazoles; Magnetic Resonance Imaging; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Zoledronic Acid | 2016 |
Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ).
Topics: Animals; Antibodies, Monoclonal; Antigens, CD; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Pamidronate; Receptors, Antigen, T-Cell, gamma-delta; Semaphorins; T-Lymphocytes; Zoledronic Acid | 2016 |
Experimental model of osteonecrosis of the jaw in rats treated with zoledronic acid.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Imidazoles; Male; Mandibular Injuries; Rats; Rats, Wistar; Zoledronic Acid | 2017 |
Do osteoporotic fractures constitute a greater recalcitrant challenge for skeletal regeneration? Investigating the efficacy of BMP-7 and zoledronate treatment of diaphyseal fractures in an open fracture osteoporotic rat model.
Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 7; Diaphyses; Diphosphonates; Disease Models, Animal; Drug Evaluation; Drug Therapy, Combination; Female; Femoral Fractures; Fracture Healing; Fractures, Open; Imidazoles; Osteoporotic Fractures; Ovariectomy; Radiography; Rats, Sprague-Dawley; Stress, Mechanical; X-Ray Microtomography; Zoledronic Acid | 2017 |
Skeletal Site-specific Effects of Zoledronate on in vivo Bone Remodeling and in vitro BMSCs Osteogenic Activity.
Topics: Alveolar Bone Loss; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Remodeling; Cell Proliferation; Cells, Cultured; Diphosphonates; Disease Models, Animal; Female; Gene Expression Regulation; Humans; Imidazoles; Maxilla; Mesenchymal Stem Cells; Osteoprotegerin; RANK Ligand; Rats; Rats, Sprague-Dawley; Wnt3A Protein; Zoledronic Acid | 2017 |
Dental extraction following zoledronate, induces osteonecrosis in rat's jaw.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Imidazoles; Male; Postoperative Complications; Random Allocation; Rats; Rats, Wistar; Tooth Extraction; Zoledronic Acid | 2017 |
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Cells; Breast Neoplasms; Cell Line, Tumor; Colony-Forming Units Assay; Diphosphonates; Disease Models, Animal; Extracellular Matrix; Female; Hematopoiesis; Hematopoietic Stem Cells; Humans; Imidazoles; Leukocyte Count; Mice; Neovascularization, Pathologic; Osteoblasts; Osteoclasts; X-Ray Microtomography; Zoledronic Acid | 2017 |
Rejuvenating premature aging.
Topics: Animals; Bone Density Conservation Agents; Cell Nucleus; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination; Farnesyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Lamin Type A; Longevity; Mice; Mice, Knockout; Nuclear Proteins; Pravastatin; Prenylation; Progeria; Protein Precursors; Tumor Suppressor Protein p53; Zoledronic Acid | 2008 |
Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Drug Delivery Systems; Female; Femur; Imidazoles; Implants, Experimental; Osteoporosis; Pilot Projects; Sheep; Treatment Outcome; Zoledronic Acid | 2008 |
Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Caspase 3; Cell Proliferation; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Ki-67 Antigen; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Research Design; Tomography, X-Ray Computed; Zoledronic Acid | 2008 |
Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Diseases, Metabolic; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Injections, Intravenous; Jaw Diseases; Mandibular Diseases; Maxillary Diseases; Oral Ulcer; Osteonecrosis; Prospective Studies; Rats; Rats, Sprague-Dawley; Zoledronic Acid | 2009 |
Are new-generation bisphosphonates effective for the inhibition of calcium oxalate stone formation in a rat model?
Topics: Animals; Calcium; Calcium Oxalate; Clodronic Acid; Creatinine; Diphosphonates; Disease Models, Animal; Imidazoles; Injections, Intraperitoneal; Male; Rats; Rats, Sprague-Dawley; Urinary Bladder Calculi; Zinc; Zoledronic Acid | 2008 |
Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model.
Topics: Animals; Cell Proliferation; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Imidazoles; Lung Neoplasms; Mice; Osteosarcoma; Protein Prenylation; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2009 |
Comment on: Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Glucocorticoids; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Rats; Tooth Extraction; Zoledronic Acid | 2009 |
Zoledronate reduces unwanted bone resorption in intercalary bone allografts.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Bone Remodeling; Bone Resorption; Bone Transplantation; Diphosphonates; Disease Models, Animal; Femur; Graft Survival; Imidazoles; Male; Radiography; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Transplantation, Homologous; Zoledronic Acid | 2010 |
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Humans; Hyperparathyroidism; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Transgenic; Osteoclasts; Osteoprotegerin; Porosity; Primary Myelofibrosis; Receptor, Parathyroid Hormone, Type 1; Tomography, X-Ray Computed; Zoledronic Acid | 2009 |
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Mice; Mice, SCID; Multiple Myeloma; Protein Prenylation; Transplantation, Heterologous; Zoledronic Acid | 2010 |
Mandibular necrosis in beagle dogs treated with bisphosphonates.
Topics: Alendronate; Alveolar Process; Animals; Bone Density Conservation Agents; Bone Matrix; Bone Remodeling; Cell Death; Cell Survival; Coloring Agents; Diphosphonates; Disease Models, Animal; Dogs; Female; Haversian System; Imidazoles; L-Lactate Dehydrogenase; Mandibular Diseases; Osteocytes; Osteonecrosis; Ribs; Rosaniline Dyes; Time Factors; Zoledronic Acid | 2009 |
Effect of locally administered zoledronic acid on injury-induced intramembranous bone regeneration and osseointegration of a titanium implant in rats.
Topics: Animals; Biocompatible Materials; Bone Regeneration; Diphosphonates; Disease Models, Animal; Femur; Fracture Fixation, Intramedullary; Imidazoles; Implants, Experimental; Injections, Intralesional; Male; Osseointegration; Probability; Random Allocation; Rats; Rats, Wistar; Reference Values; Risk Assessment; Titanium; Zoledronic Acid | 2009 |
The effect of soaking allograft in bisphosphonate: a pilot dose-response study.
Topics: Animals; Arthroplasty, Replacement; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Transplantation; Diphosphonates; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Humerus; Imidazoles; Osseointegration; Pilot Projects; Prostheses and Implants; Prosthesis Design; Titanium; Transplantation, Homologous; Zoledronic Acid | 2010 |
A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Endothelin-1; Humans; Imidazoles; Killer Cells, Natural; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Mice, SCID; Osteoblasts; Osteolysis; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2009 |
A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration.
Topics: Absorptiometry, Photon; Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Glucocorticoids; Imidazoles; Lumbar Vertebrae; Male; Methylprednisolone; Orthopedic Fixation Devices; Osseointegration; Osteoporosis; Prostheses and Implants; Rabbits; Tibia; Titanium; Zoledronic Acid | 2010 |
Jaw bone changes in rats after treatment with zoledronate and pamidronate.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Femur; Imidazoles; Inflammation; Mandible; Osteonecrosis; Pamidronate; Rats; Rats, Sprague-Dawley; Single-Blind Method; Time Factors; Zoledronic Acid | 2010 |
Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats.
Topics: Animals; Apoptosis; Diphosphonates; Disease Models, Animal; Femur; Gene Expression Regulation; Humans; Imidazoles; Inflammation; Jaw Diseases; Oligonucleotide Array Sequence Analysis; Osteoclasts; Osteogenesis; Osteonecrosis; Rats; Rats, Sprague-Dawley; Tooth Extraction; Vitamin D; Vitamin D Deficiency; Zoledronic Acid | 2010 |
Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice.
Topics: Animals; Cytokines; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Immunosuppressive Agents; Immunotherapy; Jaw Diseases; Mesenchymal Stem Cell Transplantation; Mice; Mice, Inbred C57BL; Mice, Nude; Osteonecrosis; T-Lymphocytes, Regulatory; Zoledronic Acid | 2010 |
A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Injections, Intravenous; Jaw Diseases; Maxillary Diseases; Osteonecrosis; Radionuclide Imaging; Rats; Rats, Wistar; Reproducibility of Results; Tooth Extraction; Zoledronic Acid | 2010 |
Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice.
Topics: Acid Phosphatase; Animals; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Cell Adhesion Molecules; Collagen Type I; Diphosphonates; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Fluorescent Antibody Technique, Direct; Imidazoles; Immunoenzyme Techniques; Isoenzymes; Mice; Mice, Inbred BALB C; Mice, Knockout; Ovariectomy; Peptide Fragments; Peptides; Procollagen; Reproducibility of Results; Tartrate-Resistant Acid Phosphatase; Tibia; Zoledronic Acid | 2010 |
Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination; Imidazoles; Jaw; Osteonecrosis; Random Allocation; Rats; Rats, Wistar; Tooth Extraction; Zoledronic Acid | 2011 |
Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Cell Survival; Diphosphonates; Disease Models, Animal; Estrogens; Female; Imidazoles; Osteocytes; Osteoporosis; Ovariectomy; Sheep; Zoledronic Acid | 2011 |
Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.
Topics: Acid Phosphatase; Animals; Bone Density Conservation Agents; Bone Resorption; Calcium; Carcinoma, Squamous Cell; Cats; Diphosphonates; Disease Models, Animal; Imidazoles; Isoenzymes; Luciferases; Male; Mice; Mice, Nude; Mouth Neoplasms; Osteoclasts; Osteolysis; Tartrate-Resistant Acid Phosphatase; Transplantation, Heterologous; X-Ray Microtomography; Zoledronic Acid | 2010 |
Zoledronate inhibits intimal hyperplasia in balloon-injured rat carotid artery.
Topics: Administration, Topical; Angioplasty, Balloon; Animals; Cardiovascular Agents; Carotid Artery Injuries; Carotid Artery, Common; Cell Proliferation; Diphosphonates; Disease Models, Animal; Hyperplasia; Image Processing, Computer-Assisted; Imidazoles; Immunohistochemistry; Injections, Intravenous; Male; Proliferating Cell Nuclear Antigen; Rats; Rats, Sprague-Dawley; Time Factors; Tunica Intima; Zoledronic Acid | 2011 |
The effects of zoledronic acid on neointimal hyperplasia: a rabbit carotid anastomosis model.
Topics: Actins; Anastomosis, Surgical; Animals; Carotid Arteries; Diphosphonates; Disease Models, Animal; Hyperplasia; Imidazoles; Immunohistochemistry; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Muscle, Smooth, Vascular; Neointima; Rabbits; Random Allocation; Zoledronic Acid | 2011 |
The effects of zoledronic acid and hyperbaric oxygen on posterior lumbar fusion in a rabbit model.
Topics: Animals; Bone Density Conservation Agents; Bone Transplantation; Diphosphonates; Disease Models, Animal; Hyperbaric Oxygenation; Ilium; Imidazoles; Lumbar Vertebrae; Male; Palpation; Rabbits; Radiography; Spinal Fusion; Stress, Mechanical; Treatment Outcome; Zoledronic Acid | 2011 |
Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate.
Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Combined Modality Therapy; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fracture Fixation, Internal; Fracture Healing; Fractures, Ununited; Imidazoles; Mice; Mice, Knockout; Neurofibromatosis 1; Postoperative Care; Pseudarthrosis; Recombinant Proteins; Tibial Fractures; Treatment Outcome; X-Ray Microtomography; Zoledronic Acid | 2011 |
Manipulation of the anabolic and catabolic responses with BMP-2 and zoledronic acid in a rat femoral fracture model.
Topics: Anabolic Agents; Animals; Biomechanical Phenomena; Bone Morphogenetic Protein 2; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination; Femoral Fractures; Humans; Imidazoles; Male; Palpation; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Transforming Growth Factor beta; X-Ray Microtomography; Zoledronic Acid | 2011 |
The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats.
Topics: Animals; Biomarkers; Bone Density; Bone Density Conservation Agents; Bony Callus; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Fracture Healing; Imidazoles; Osteoporotic Fractures; Osteoprotegerin; Parathyroid Hormone; RANK Ligand; Rats; Rats, Sprague-Dawley; Tibial Fractures; X-Ray Microtomography; Zoledronic Acid | 2012 |
Development of a rat model of bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Collagen; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Pyridinium Compounds; Random Allocation; Rats; Rats, Sprague-Dawley; Tooth Extraction; Tooth Socket; Vascular Endothelial Growth Factor A; Wound Healing; X-Ray Microtomography; Zoledronic Acid | 2012 |
Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Cell Proliferation; Diphosphonates; Disease Models, Animal; Disease Progression; Doxorubicin; Female; Imidazoles; Immunocompetence; Macrophages; Male; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Zoledronic Acid | 2012 |
Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.
Topics: Animals; Blotting, Western; Bone Density Conservation Agents; Bone Marrow; Bone Resorption; Cell Differentiation; Cell Proliferation; Cells, Cultured; Chemokine CCL3; Diphosphonates; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Hematopoiesis; Humans; Imidazoles; Immunocompetence; Immunoenzyme Techniques; Leukemia, Myeloid; Male; Mice; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spleen; Zoledronic Acid | 2012 |
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.
Topics: Adenocarcinoma; Animals; Bone Marrow Cells; Cell Differentiation; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Mice; Mice, Inbred C57BL; Myeloid Cells; Pancreatic Neoplasms; Tumor Microenvironment; Up-Regulation; Zoledronic Acid | 2012 |
Orthodontic tooth movement and root resorption in ovariectomized rats treated by systemic administration of zoledronic acid.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Osteoporosis; Postmenopause; Rats; Rats, Wistar; Root Resorption; Tooth Movement Techniques; Zoledronic Acid | 2012 |
Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Disease Progression; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Transcriptome; Zoledronic Acid | 2012 |
Skeletal effects of zoledronic acid in an animal model of chronic kidney disease.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diaphyses; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Femur; Imidazoles; Male; Osteogenesis; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Tibia; Zoledronic Acid | 2013 |
Effect and mechanism of zoledronate on prevention of collapse in osteonecrosis of the femoral head.
Topics: Animals; Diphosphonates; Disease Models, Animal; Femur Head; Femur Head Necrosis; Imidazoles; Male; Osteoblasts; Osteoclasts; Rats; Rats, Sprague-Dawley; Zoledronic Acid | 2012 |
Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.
Topics: Androgens; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Bone Density Conservation Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Octreotide; Orchiectomy; Prostatic Neoplasms; ras Proteins; Receptors, Somatostatin; Somatostatin; Zoledronic Acid | 2013 |
Variations in nanomechanical properties and tissue composition within trabeculae from an ovine model of osteoporosis and treatment.
Topics: Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Imidazoles; Nanotechnology; Osteoporosis; Raloxifene Hydrochloride; Sheep; Spectrum Analysis, Raman; Zoledronic Acid | 2013 |
[Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cytotoxicity, Immunologic; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Interferon-gamma; Leukocytes, Mononuclear; Lymphocyte Activation; Mice; Osteosarcoma; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2013 |
Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Resorption; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Femur; Humans; Imidazoles; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Weight-Bearing; Zoledronic Acid | 2003 |
Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Drug Combinations; Female; Fluorouracil; Imidazoles; Luciferases; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Osteoclasts; Tegafur; Uracil; Zoledronic Acid | 2003 |
Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Topics: Animals; Apoptosis; Blotting, Western; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Separation; Cell Survival; Diphosphonates; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Imidazoles; Luciferases; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Neoplasm Invasiveness; Neoplasm Metastasis; Osteoclasts; Time Factors; Zoledronic Acid | 2004 |
Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis.
Topics: Acid Phosphatase; Animals; Bone Density; Bone Regeneration; Bony Callus; Cartilage; Diphosphonates; Disease Models, Animal; Imidazoles; Isoenzymes; Male; Osteoblasts; Osteoclasts; Osteogenesis, Distraction; Rabbits; Tartrate-Resistant Acid Phosphatase; Tibia; Time Factors; Zoledronic Acid | 2004 |
Zoledronic acid improves femoral head sphericity in a rat model of perthes disease.
Topics: Animals; Bone Resorption; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Femur Head; Imidazoles; Legg-Calve-Perthes Disease; Rats; Rats, Inbred SHR; Zoledronic Acid | 2005 |
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Inbred C3H; Osteosarcoma; Survival Analysis; Zoledronic Acid | 2005 |
Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog.
Topics: Animals; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Femur; Imidazoles; Male; Microscopy, Electron, Scanning; Osteogenesis; Pliability; Polyethylene; Prosthesis Failure; Scattering, Radiation; Spectrometry, X-Ray Emission; X-Ray Diffraction; Zoledronic Acid | 2005 |
Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo.
Topics: Animals; Cell Division; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Etidronic Acid; Imidazoles; Mesothelioma; Mice; Phosphorylation; Risedronic Acid; Zoledronic Acid | 2006 |
Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Doxycycline; Drug Synergism; Female; Humans; Imidazoles; Mice; Mice, Nude; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2007 |
Articular damage is associated with intraosseous inflammation in the subchondral bone marrow of joints affected by experimental inflammatory arthritis and is modified by zoledronate treatment.
Topics: Animals; Arthritis, Experimental; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Diseases; Carrageenan; CD11b Antigen; CD3 Complex; CD4 Antigens; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Inflammation; Joints; Rabbits; Rats; Rats, Sprague-Dawley; Spleen; Zoledronic Acid | 2007 |
Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.
Topics: Animals; Bone Resorption; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Immunologic; Female; Hydroxycholecalciferols; Hypercalcemia; Imidazoles; Immunity, Innate; Immunoglobulin G; Influenza A Virus, H3N2 Subtype; Longitudinal Studies; Male; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Recombinant Fusion Proteins; Zoledronic Acid | 2007 |
Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice.
Topics: Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cell Survival; Cells, Cultured; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination; Energy Metabolism; Female; Femur; Haplotypes; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurofibromatosis 1; Neurofibromin 1; Osteoblasts; Skull; Tibia; Transforming Growth Factor beta; Zoledronic Acid | 2008 |
Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Marrow Cells; Bone Neoplasms; Bone Remodeling; Cell Cycle; Cell Proliferation; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Male; Mice; Mice, Inbred C3H; Osteoblasts; Osteogenesis; Osteosarcoma; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Zoledronic Acid | 2008 |
Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Carcinoma; Chemotherapy, Adjuvant; Diphosphonates; Disease Models, Animal; Female; Femoral Neoplasms; Imidazoles; Mice; Osteolysis; Tensile Strength; Tumor Burden; Zoledronic Acid | 2008 |
Development of a low-dose anti-resorptive drug regimen reveals synergistic suppression of bone formation when coupled with disuse.
Topics: Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Resorption; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Femur; Hindlimb Suspension; Imidazoles; Mice; Mice, Inbred C57BL; Osteoblasts; Osteogenesis; Osteoporosis; Osteoprotegerin; Space Flight; Tomography, X-Ray Computed; Weightlessness Countermeasures; Zoledronic Acid | 2008 |
Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography.
Topics: Animals; Bone Demineralization, Pathologic; Bone Density Conservation Agents; Bone Resorption; Compressive Strength; Diphosphonates; Disease Models, Animal; Elasticity; Female; Imidazoles; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Stress, Mechanical; Tibia; Tomography, X-Ray Computed; Zoledronic Acid | 2008 |
Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis.
Topics: Animals; Ankylosis; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Imidazoles; Joints; Male; Mice; Mice, Inbred DBA; Osteoclasts; Spondylarthritis; Treatment Failure; Zoledronic Acid | 2008 |
Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.
Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Image Processing, Computer-Assisted; Imidazoles; Mice; Osteoclasts; Osteolysis; Osteoprotegerin; Polyethylene; Prosthesis Failure; Skull; Surface Properties; Tomography, X-Ray Computed; Zoledronic Acid | 2008 |
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Topics: Adenocarcinoma; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Transformed; Diphosphonates; Disease Models, Animal; Dogs; Imidazoles; Incidence; Luminescent Proteins; Male; Mice; Mice, Nude; Osteoclasts; Osteolysis; Prostatic Neoplasms; Radiography; Zoledronic Acid | 2008 |
Zoledronate: the preclinical pharmacology.
Topics: Animals; Bone Resorption; Cholecalciferol; Depression, Chemical; Diphosphonates; Disease Models, Animal; Female; Hypercalcemia; Imidazoles; Ovariectomy; Pamidronate; Parathyroidectomy; Rats; Thyroidectomy; Zoledronic Acid | 1996 |
Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis.
Topics: Animals; Arthritis, Rheumatoid; Carrageenan; Cartilage, Articular; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Injections, Subcutaneous; Knee Joint; Osteochondritis; Rabbits; Reference Values; Synovial Membrane; Zoledronic Acid | 1999 |
Changes in cross-sectional geometry of the distal femoral metaphysis associated with inflammatory arthritis are reduced by a bisphosphonate (zoledronate).
Topics: Animals; Arthritis; Carrageenan; Diphosphonates; Disease Models, Animal; Femur; Image Processing, Computer-Assisted; Imidazoles; Injections, Subcutaneous; Knee Joint; Rabbits; Zoledronic Acid | 2000 |
Bisphosphonates and nephrocalcinosis in a rabbit leg lengthening model: a histological and therapeutic comparison.
Topics: Animals; Bone Density; Bone Regeneration; Diphosphonates; Disease Models, Animal; Imidazoles; Kidney; Male; Nephrocalcinosis; Osteogenesis, Distraction; Pamidronate; Rabbits; Zoledronic Acid | 2001 |